Xenon Pharmaceuticals (XENE) Other financing activities (2015 - 2026)

Xenon Pharmaceuticals (XENE) has 11 years of Other financing activities data on file, last reported at $5.5 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 376.72% year-over-year to $5.5 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 676.13% increase from a year earlier, with the FY2025 full-year figure at $5.0 million, up 10457.45% from the prior year.
• Other financing activities for Q1 2026 stood at $5.5 million, up from $1.4 million in the prior quarter.
• Over the last five years, Other financing activities for XENE reached as high as $5.5 million in Q1 2026 and fell as low as $6000.0 in Q4 2022.
• Historically, Other financing activities has averaged $1.5 million across 4 years, with a median of $1.2 million in 2025.
• Across the five-year window, Other financing activities slumped 60.0% in 2022 and jumped 2848.94% in 2025, its largest moves.
• Year by year, Other financing activities stood at $6000.0 in 2022, then surged by 683.33% to $47000.0 in 2024, then soared by 2848.94% to $1.4 million in 2025, then jumped by 295.89% to $5.5 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $5.5 million in Q1 2026, $1.4 million in Q4 2025, and $2.4 million in Q3 2025.